Результаты поиска

Recent advances in the management of systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease presenting highly heterogeneous clinical manifestations and multi-systemic involvement. Patients are susceptible to relapse- and remission, thus making management challenging. Moreover, a considerable number of side effects may occur with conventional therapies; therefore, there is clearly a need for new therapeutic strategies. Since the pathogenesis of SLE is highly complex, it is far from being fully understood. However, greater understanding of the pathways and of the cellular and molecular mediators involved in SLE is being

Совпадение в полном тексте источника
… Arthritis Rheum. 2006;54(5):1390–400. 10.1002/art.21778 12. … Arthritis Rheum. 2012;64(11):3666–76. 10.1002/art.34632 92. …

Scleroderma-Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single-Center Prospective Registry.

OBJECTIVE: Early diffuse cutaneous systemic sclerosis (dcSSc) is associated with substantial disease-specific mortality.  Scleroderma-specific autoantibodies (SSc-Ab) may influence disease course, but their prognostic value in very early dcSSc remains unclear. We examined associations between autoantibody profiles and disease trajectories for clinical events in a prospective single-center cohort. METHODS: We retrospectively analyzed prospectively collected data from a subset of patients enrolled in an early SSc registry between October 2012 and July 2021, including those with early dcSSc or i

Совпадение в полном тексте источника
… Ann Rheum Dis 1983;42:23–27. 14. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010;37:42–53. 15. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35–42. 16. Nihtyanova SI, Denton CP. … Ann Rheum Dis 2015;74:1124–1131. 23. Hoffmann‐Vold AM, Allanore Y, Alves M, et al; EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis‐associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021;80:219–227. 24. …

Osteoarthritis of the knee - biochemical aspect of applied therapies: a review.

The most prevalent form of arthritis is osteoarthritis (OA) of the knee, which is characterized by a degeneration of articular cartilage resulting in the development of osteophytes, or bone spurs. Main goals of OA treatment are to reduce pain, slow the disease progression, and improve joint function and the quality of life. The purpose of this study was to verify all the therapies recommended by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) from the biochemical point of view. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the synthesi

Совпадение в полном тексте источника
… M Adami S Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee:Results of the two-year multinational knee osteoarthritis structural arthritis study Arthritis Rheum … O Cooper C Pelletier JP Branco J Brandi ML Guillemin F An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally:A report from a task force of the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) Semin Arthritis Rheum …

Malignancies in systemic rheumatic diseases: A mini review.

There is an increased risk of malignancies in patients with many systemic rheumatic diseases, which negatively impact on their quality of life. The risk and types of malignancies can differ by the type of rheumatic diseases. Possible mechanisms linking them are dynamic and complicated, including chronic inflammation and damage in rheumatic disease, inability to clear oncogenic infections, shared etiology and some anti-rheumatic therapies. Although certain disease-modifying anti-rheumatic drugs (DMARDs) have been proved to be potentially carcinogenic, the majority of them were not associated wi…

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.

OBJECTIVES: Informing an international task force updating the consensus statement on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) selectively targeting interleukin-6 (IL-6) pathway in the context of immune-mediated inflammatory diseases. METHODS: A systematic literature research of all publications on IL-6 axis inhibition with bDMARDs published between January 2012 and December 2020 was performed using MEDLINE, EMBASE and Cochrane CENTRAL databases. Efficacy and safety outcomes were assessed in clinical trials including their long-term extensions and obse…

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management.

Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders. Types II and III are known as mixed CG (MC): Type II consists of polyclonal IgG and monoclonal IgM with rheumatoid factor (RF) activity, whereas Type III includes polyclonal IgG and polyclonal IgM with RF activity. MC is predominantly associated with hepatitis C virus (HCV) infection and involve…

Показатели качества в системном склерозе

Повышение качества - это новая область, в которой применяются принципы совершенствования науки и используются методы измерения в целях улучшения ухода за пациентами. Системный склероз (SSc) — системное аутоиммунное ревматическое заболевание, связанное с увеличением нагрузки на здравоохранение, расходов, заболеваемости и смертности. Неоднократно отмечаются пробелы в оказании медицинской помощи пациентам, страдающим SSc. В этой статье мы введем дисциплину повышения качества и использования показателей качества. Мы резюмируем и сравнительно оцениваем three - наборы качественных показателей, котор

Совпадение в аннотации оригинала
Quality improvement is an emerging field, that applies principles of improvement science and utilizes measurement methods with the aim of improving patient care. Systemic sclerosis (SSc) is a systemic autoimmune rheumatic disease associated with increased healthcare burden, cost, morbidity, and mortality. Gaps in delivering care to patients with SSc have bee…

Rare complication of a commonly used antihypertensive agent: A case of hydralazine-induced ANCA-associated vasculitis presenting as rapidly progressive glomerulonephritis.

Hydralazine-induced ANCA-associated vasculitis is a rare clinical entity, with complications including rapidly progressive glomerulonephritis, pulmonary hemorrhage, and pulmonary-renal syndrome. We present this case to highlight the clinical features that support this challenging diagnosis and to emphasize the importance of prompt recognition and aggressive intervention given its significant morbidity and mortality.

Совпадение в полном тексте источника
… Semin Arthritis Rheum. 2018;48(2):283‐287. 8. Ntatsaki E, Watts RA, Scott DGI. Epidemiology of ANCA‐associated vasculitis. Rheum Dis Clin North Am. 2010;36(3):447‐461. 9. Xiao H, Heeringa P, Hu P, et al. … Arthritis Rheum. 2000;43(2):405‐413. 13. Radić M, Martinović Kaliterna D, Radić J. Drug‐induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70(1):12‐17. 14. Aeddula NR, Pathireddy S, Ansari A, Juran PJ. …

Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are severe autoimmune disorders characterized by necrotizing small-vessel inflammation, and are classified among anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). Standard induction therapy combines glucocorticoids (GCs) with rituximab (RTX) or cyclophosphamide (CYC), with growing emphasis on GC minimization and selective use of avacopan in patients at high risk of GC toxicity. For maintenance therapy, fixed-interval RTX generally outperforms conventional oral agents and biomarker-guided re-dosin

Совпадение в полном тексте источника
… Ann Rheum Dis 83:233–241. 10.1136/ARD-2023-224623 10.1136/ard-2023-224623 37918894 9. Alba MA Flores-Suárez LF Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why? … Ann Rheum Dis 83:30–47. 10.1136/ARD-2022-223764 36927642 10.1136/ard-2022-223764 13. …

B-cell targeted therapeutics in clinical development.

B lymphocytes are the source of humoral immunity and are thus a critical component of the adaptive immune system. However, B cells can also be pathogenic and the origin of disease. Deregulated B-cell function has been implicated in several autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B cells contribute to pathological immune responses through the secretion of cytokines, costimulation of T cells, antigen presentation, and the production of autoantibodies. DNA-and RNA-containing immune complexes can also induce the production of type …

The Advantages of Radiofrequency Echographic MultiSpectrometry in the Evaluation of Bone Mineral Density in a Population with Osteoarthritis at the Lumbar Spine.

BACKGROUND: Osteoarthritis (OA) in the lumbar spine can potentially lead to an overestimation of bone mineral density (BMD), and this can be a challenge in accurately diagnosing conditions like osteoporosis, where precise measurement of BMD is crucial. Radiofrequency Echographic Multi Spectrometry (REMS) is being recognized as an innovative diagnostic tool for assessing bone status. The purpose of this study was to evaluate whether the use of REMS may enhance the identification of osteoporosis in patients with osteoarthritis. METHODS: A cohort of 500 patients (mean age: 63.9 ± 11.2 years) dia

Совпадение в полном тексте источника
… Rheum. Dis. 1994;53:158–162. doi: 10.1136/ard.53.3.158. 2. Im G.I., Kim M.K. The relationship between osteoarthritis and osteoporosis. J. Bone Miner. Metab. 2014;32:101–109. doi: 10.1007/s00774-013-0531-0. 3. … Rheum. Dis. 1992;51:1025–1026. doi: 10.1136/ard.51.9.1025. 9. Stewart A., Black A.J. Bone mineral density in osteoarthritis. Curr. Opin. Rheumatol. 2000;12:464–477. doi: 10.1097/00002281-200009000-00021. 10. Martineau P., Bazarjani S., Zuckier L.S. …

Immune mechanism of low bone mineral density caused by ankylosing spondylitis based on bioinformatics and machine learning.

Background and Objective: This study aims to find the key immune genes and mechanisms of low bone mineral density (LBMD) in ankylosing spondylitis (AS) patients. Methods: AS and LBMD datasets were downloaded from the GEO database, and differential expression gene analysis was performed to obtain DEGs. Immune-related genes (IRGs) were obtained from ImmPort. Overlapping DEGs and IRGs got I-DEGs. Pearson coefficients were used to calculate DEGs and IRGs correlations in the AS and LBMD datasets. Louvain community discovery was used to cluster the co-expression network to get gene modules. The modu

Совпадение в полном тексте источника
… Arthritis Rheum. 38 , 499 – 505 . 10.1002/art.1780380407 7718003 Braun J. Sieper J. ( 2007 ). Ankylosing spondylitis . Lancet 369 , 1379 – 1390 . 10.1016/S0140-6736(07)60635-7 17448825 Burja B. Mertelj T. Frank-Bertoncelj M. ( 2020 ). … Arthritis Rheum. 53 , 151974 . 10.1016/j.semarthrit.2022.151974 35150984 Ranganathan V. Gracey E. Brown M. A. Inman R. D. Haroon N. ( 2017 ). Pathogenesis of ankylosing spondylitis - recent advances and future directions . Nat. Rev. …

Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.

Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjögren's syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and refractory/intolerance to conventional immunosuppressants demand other options, namely biological drugs, and small molecules. We aimed to define evidence and practice-based guidance for the off-label use of biologics in SLE, APS, and SS. Recommendations were made by an independent expert panel, following a comprehensive literature review and two consensus rounds. The panel included 17 internal medicine experts with recognized practice

Совпадение в полном тексте источника
… Arthritis Rheum ( 2012 ) 64 ( 4 ): 1215–26 . doi: 10.1002/art.34359 22231479 29 McCarthy EM Sutton E Nesbit S White J Parker B Jayne D . … Arthritis Rheum ( 2010 ) 62 ( 10 ): 3077–87 . doi: 10.1002/art.27601 20533545 96 Chamberlain C Colman PJ Ranger AM Burkly LC Johnston GI Otoul C . …

Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?

BACKGROUND: Exploring the cancer risks of rheumatoid arthritis (RA) patients with disease-modifying anti-rheumatic drugs (DMARDs) can help detect, evaluate, and treat malignancies at an early stage for these patients. Thus, a comprehensive analysis was conducted to determine the cancer risk of RA patients using different types of DMARDs and analyze their relationship with tumor mutational burdens (TMBs) reflecting immunogenicity. METHODS: A thorough search of PubMed, EMBASE, Web of Science, and Medline was conducted up to 20 August 2022. Standardized incidence ratios (SIRs) were constructed w…

CAR-T Therapy Can Be a Useful Treatment Modality for More Than Just Hematologic Malignancies.

Chimeric antigen receptor-T-cell (CAR-T) therapy for hematologic malignancies has made significant advancements over the years, and it is now incorporated as a treatment algorithm. Early phase clinical trials are underway for various solid tumors, and the effectiveness of CAR-T cell therapy has been demonstrated for specific types of glioma and several solid tumors. However, its efficacy does not match that observed in hematological malignancies. Recently, a case series reported CAR-T cell therapy targeting CD19 for autoimmune diseases such as systemic lupus erythematosus, leading to a dramati

Совпадение в полном тексте источника
… Arthritis Rheum 62: 222-233, 2010. 21. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69: 409-412, 2010. 22. … Ann Rheum Dis 83: 696-699, 2024. 33. Chasov V, Zmievskaya E, Ganeeva I, et al. Immunotherapy strategy for systemic autoimmune diseases: betting on CAR-T cells and antibodies. Antibodies (Basel) 13: 2024. 34. Eichholz K, Fukazawa Y, Peterson CW, et al. …

Гематологические маньяки маскируются как ревматологические заболевания: серия дел и обзор.

RATALE: Гематологическая недостаточность может имитировать ревматологические заболевания, создавая серьезную диагностическую проблему из-за перекрывающихся клинических особенностей. В настоящем исследовании подчеркивается 5 - случаи гематологических маньяков, представляющих собой ревматологические расстройства, и обсуждаются связанные с этим диагностические сложности. БОЛЕЕ ТРУДЯЩИЕСЯ: 64 в адрес 78, с различными рематологическими симптомами, включая полиартрит, васкулит, явление Рейно, и такими систематическими симптомами, как потеря веса, усталость и ночной пот. В ходе первоначальной эксперт

Совпадение в аннотации оригинала
RATIONALE: Hematologic malignancies can mimic rheumatologic diseases, presenting a significant diagnostic challenge due to overlapping clinical features. This study highlights 5 cases of hematologic malignancies presenting as rheumatologic disorders and discusses the diagnostic complexities involved. PATIENT CONCERNS: The patients, aged 64 to 78, presented …

CAR-T cell therapy: A new dawn in the treatment of autoimmune disease.

Autoimmune diseases (AIDs) are a class of diseases caused by autoimmune intolerance, which can be divided into systemic and organ-specific diseases. AIDs affect approximately 10% of the global population and rank among the leading causes of disability and mortality. At present, immunosuppressive agents are the first choice for the treatment of AIDs. B-cell-targeted therapies-particularly CD20 monoclonal antibodies-have brought new hope for systemic AIDs, yet a subset of patients still respond poorly. As a rapidly developing cellular immunotherapy technology, Chimeric antigen receptor T cell (C

Совпадение в полном тексте источника
… Ann Rheum Dis. 2024;83:1597–98. doi: 10.1136/ard-2024-226017. 44. Brand DD, Sandal I, Luo J, Albritton L, Radic M, Rosloniec EF. … Ann Rheum Dis. 2024;83(4):499–507. doi: 10.1136/ard-2023-224875. 50. Wang J, Alkrekshi A, Dasari S, Lin HC, Elantably D, Armashi ARA. …

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Methotrexate, a structural analogue of folic acid, is one of the most effective and extensively used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune diseases. In this paper, we take an overview of the present state of knowledge with regards to complex mechanisms of methotrexate action and its applications as immunosuppressive drug or chemotherapeutic agent in oncological combination therapy. In addition, the issue of the potential benefits of methotrexate in the development of neurological disorders in Alzheimer's disease or myasthenia gravis will be discuss

Совпадение в полном тексте источника
… Arthritis Rheum. 2003;48:240–247. doi: 10.1002/art.10712. 46. Varani K., Vincenzi F., Tosi A., Targa M., Masieri F.F., Ongaro A., De Mattei M., Massari L., Borea P.A. Expression and Functional Role of Adenosine Receptors in Regulating Inflammatory Responses in Human Synoviocytes. Br. J. … Rheum. Mal. Osteoartic. 1992;59:587–591. 52. Brody M., Bohm I., Bauer R. Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin-1 beta to the interleukin-1 receptor on target cells. Eur. J. Chem. Clin. …

Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of SLE is the production of autoantibodies, with the formation of immune complexes that precipitate at the vascular level, causing organ damage. Although progress in understanding the pathogenesis of SLE has been slower than in other rheumatic diseases, new knowledge has recently led to the d…

Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.

Monogenic autoinflammatory diseases are rare conditions caused by genetic abnormalities affecting the innate immunity. Previous therapeutic strategies had been mainly based on results from retrospective studies and physicians' experience. However, during the last years, the significant improvement in their genetic and pathogenic knowledge has been accompanied by a remarkable progress in their management. The relatively recent identification of the inflammasome as the crucial pathogenic mechanism causing an aberrant production of interleukin 1β (IL-1β) in the most frequent monogenic autoinflamm

Совпадение в полном тексте источника
… Arthritis Rheum . ( 2008 ) 58 : 1516 – 20 . 10.1002/art.23475 18438813 84. Bodar EJ Kuijk LM Drenth JP van der Meer JW Simon A Frenkel J . On-demand anakinra treatment is effective in mevalonate kinase deficiency . Ann Rheum Dis . ( 2011 ) 70 : 2155 – 8 . 10.1136/ard.2011.149922 21859689 85. … Arthritis Rheum . ( 2011 ) 63 : 840 – 9 . 10.1002/art.30149 21360513 88. Hawkins PN Lachmann HJ Aganna E McDermott MF . Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra . Arthritis Rheum . ( 2004 ) 50 : 607 – 12 . 10.1002/art.20033 14872505 89. …